Valuation: Edgewise Therapeutics, Inc.

Market Cap 4.27B 3.75B 3.54B 3.23B 6.04B 409B 6.08B 42.37B 16.41B 209B 16.04B 15.69B 672B P/E 2026 *
64.7x
P/E 2027 * -19.4x
Enterprise Value 3.01B 2.64B 2.5B 2.28B 4.26B 289B 4.29B 29.89B 11.58B 148B 11.31B 11.07B 474B EV / Sales 2026 *
21.6x
EV / Sales 2027 * 73.8x
Free-Float
99.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Edgewise Therapeutics, Inc.

1 day-4.42%
1 week-13.20%
Current month-5.82%
1 month-11.02%
3 months-5.64%
6 months+23.17%
Current year+58.53%
1 week 38.57
Extreme 38.57
45.99
1 month 38.57
Extreme 38.57
48.51
Current year 22.78
Extreme 22.78
48.51
1 year 14.25
Extreme 14.25
48.51
3 years 5.12
Extreme 5.12
48.51
5 years 5.12
Extreme 5.12
48.51
10 years 5.12
Extreme 5.12
48.51
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 56 31/05/2017
Chief Executive Officer 65 31/07/2017
Director of Finance/CFO 55 09/11/2025
Director TitleAgeSince
Director/Board Member 65 31/05/2017
Chairman 66 31/07/2017
Director/Board Member 56 31/07/2017
Date Insider Type Main position Quantity % Market Cap. Importance
13/08/26 Sell

Chief Technology Officer

-2,919 0.0027%
12/08/26 Free

Chief Financial Officer

48,750 0.0453%
12/08/26 Exercice

General Counsel

127,514 0.1185%
Change 5-day change 1-year change 3-year change Capi.($)
-4.42%-13.20%+164.29%+564.53% 4.27B
-3.30%+1.50%+51.24%+99.26% 72.26B
+1.25%-3.01%+40.12%+77.12% 60.24B
+2.12%+5.26%+32.50%+21.28% 27.73B
-3.06%-1.81%-13.10%+357.06% 25.74B
-0.75%+2.56%+0.45%-4.46% 24.75B
+0.40%+0.75%+22.91%-9.68% 20.74B
-1.70%-2.12%+146.86%+314.52% 15.06B
+0.36%-0.34%+50.32%+166.42% 14.42B
+0.21%+1.17%-8.07%+499.10% 14.23B
Average -0.89%-0.92%+48.75%+208.52% 27.94B
Weighted average by Cap. -0.82%+0.10%+38.27%+135.77%

Financials

2026 *2027 *
Net sales 140M 122M 116M 105M 197M 13.38B 199M 1.38B 536M 6.83B 524M 513M 21.97B 42.73M 37.49M 35.41M 32.27M 60.41M 4.1B 60.84M 424M 164M 2.09B 160M 157M 6.72B
Net income 86.51M 75.91M 71.7M 65.34M 122M 8.29B 123M 858M 332M 4.24B 325M 318M 13.61B -223M -196M -185M -168M -315M -21.37B -317M -2.21B -856M -10.92B -837M -819M -35.09B
Net Debt -1.26B -1.1B -1.04B -951M -1.78B -121B -1.79B -12.49B -4.84B -61.65B -4.73B -4.62B -198B -1.12B -980M -926M -844M -1.58B -107B -1.59B -11.08B -4.29B -54.71B -4.19B -4.1B -176B
Logo Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on cardiovascular diseases. The Company is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardio metabolic conditions. The Company's pipeline comprises the EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003. EDG-7500 is a novel, oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction which is being studied in a multipart Phase 2 trial for the potential treatment of obstructive and nonobstructive HCM. The Company is also developing EDG-15400, which is in a Phase 1 trial of healthy adults with the future disease target of heart failure with preserved ejection fraction (HFpEF).
Employees
127
Date Price Change Volume
25/09/26 US$39.34 -4.42% 2,487,516
24/09/26 US$41.16 +0.27% 1,378,746
23/09/26 US$41.05 -7.77% 2,607,141
22/09/26 US$44.51 -0.29% 2,091,254
21/09/26 US$44.64 -1.50% 1,178,389
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
39.34USD
Average target price
52.62USD
Spread / Average Target
+33.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EWTX Stock